Aptose Biosciences

Company snapshot

Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (S

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aptose Biosciences. Not investment advice.

• Peer + 0 momentum

  Moleculin Biotech

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for Aptose Biosciences.

1. Jun 5, 2026 Clinical update

   APTO-253 — Phase 1

2. May 23, 2026 Clinical update

   Virulizin® — Phase 3

3. May 23, 2026 Clinical update

   GTI-2040 — Phase 2

4. May 23, 2026 Clinical update

   GTI-2040 — Phase 2

5. May 23, 2026 Clinical update

   Tuspetinib — Phase 2

View all clinical trial activity →

• What is Aptose Biosciences?

  Aptose Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker APTOF. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Myelogenous Leukemia in Relapse, Chronic Lymphocytic Leukemia, Carcinoma, Renal Cell, Advanced

• Is Aptose Biosciences publicly traded?

  Yes. Aptose Biosciences is listed with ticker APTOF on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aptose Biosciences develop or market?

  We link 1 drug profile(s) where Aptose Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aptose-biosciences#company-drugs.

• What are the latest developments for Aptose Biosciences?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Aptose Biosciences focus on?

  Aptose Biosciences focuses on Acute Myeloid Leukemia, Acute Myelogenous Leukemia in Relapse, Chronic Lymphocytic Leukemia based on our analysis of their pipeline programs and drug development activities.